HTA-compliant systematic literature reviews on clinical, economic, and humanistic aspects in COVID-19

Concurrently conducting systematic literature reviews of data supporting the clinical, economic, and humanistic value of a new therapy in COVID-19, in accordance with the requirements of national health technology assessment (HTA) bodies.

The challenge

Our client recognized that the clinical treatment landscape in COVID-19 was highly dynamic. In addition, the global epidemiology of this condition was varied and rapidly developing, and the long-term effectiveness of vaccination in the area was uncertain. To inform HTA submission materials for a new therapy in COVID-19, our client required an examination of clinical data for comparator therapies, alongside characterization of the economic and humanistic burden of this condition. In addition, reviews required for national HTA purposes must be conducted and reported according to systematic principles, and at an appropriately recent time prior to submission (for example, within six months).

The solution

We designed, and subsequently updated, a series of three systematic literature reviews to address the above research needs. Data were presented in a series of three concise written reports accompanied by detailed data extraction forms and reference packs for ease of review by colleagues and HTA assessors.

Key results

These systematic reviews demonstrated the relative success of comparator trials in this area (alongside providing a rich data source for network metaanalysis), and thoroughly explored the burden associated with this condition.

Value to the client

We provided robust and comprehensive reviews of the clinical efficacy of comparator therapies, and of the broad economic and humanistic burden of COVID-19. At-a-glance summaries were made available for comparator clinical trials (and were subsequently used to feed into dossier development), while detailed data were available for meta-analysis purposes. A comprehensive picture of the unmet need for effective therapies within COVID-19 was demonstrated through presentation of data on economic and humanistic burden of this condition.